And this NIH bigwig is now being investigated for

Quote:

---

One of the drugs implicated in the Science investigation is prasinezumab, an antibody treatment for Parkinson’s disease. Prasinezumab targets alpha-synuclein, a protein that aggregates pathologically in Parkinson’s. The drug is under development by Prothena Biosciences in collaboration with Roche; Prothena was co-founded by the late Dale Schenk, Ph.D., a neuroscientist who co-authored four foundational papers on alpha-synuclein with Masliah that are implicated in the dossier, according to Science.

In phase 2 trial data reported in Aug. 2022, prasinezumab showed no difference to placebo on measures of Parkinson’s disease progression. Another phase 2 trial is ongoing.

“Let me not put too fine a point on this: the ongoing phase 2 trial should be shut down,” Schrag said.

Another implicated med is dementia treatment cerebrolysin from Austria-based Ever Pharma, which is not approved in the United States but is available in dozens of other countries, according to Science. In addition, another alpha-synuclein drug for Parkinson’s called minzasolmin, from a company Masliah co-founded named Neuropore Therapies, is also held up by suspect research, according to Science’s findings.

---